Fig. 13.1
Indication of two-stage hepatectomy for colorectal liver metastases at Paul Brousse Hospital. (a) When the multinodular tumors are distributed unilobar and thought to be unresectable because of small future liver remnant (FLR), portal vein embolization (PVE) followed by one-stage hepatectomy is performed. (b) When the multinodular tumors are distributed bilobar but the largest tumor size is ≤30 mm and the tumor number in the FLR ≤3, standard one-stage hepatectomy with simultaneous local ablation therapy is performed. (c) When the multinodular tumors are distributed bilobar, the largest tumor size is >30 mm and the tumor number in the FLR >3, two-stage hepatectomy (TSH) is performed
Table 13.1
Demographics of studies of two-stage hepatectomy for colorectal liver metastases in the literature
Study | Year | Country | Study periods | Total No. of surgically treated pts. for CLM | No. of pts. planned for TSH | Percentage of pts. planned for TSH (%) |
---|---|---|---|---|---|---|
Lygidakis et al. | 2004 | Greece | 1991–2003 | NR | 62 | NR |
Garcea et al. | 2004 | UK | 2001–2003 | 446 | 11 | 3 |
Pamecha et al. | 2008 | UK | 1999–2005 | 280 | 14 | 5 |
Homayounfar et al. | 2009 | Germany | 2005–2007 | NR | 24 | NR |
Tsai et al. | 2010 | USA | 1994–2008 | 720 | 45 | 6 |
Karoui et al. | 2010 | France | 2000–2008 | NR | 33 | NR |
Tsim et al. | 2011 | UK | 2003–2006 | 131 | 38 | 29 |
Brouquet et al. | 2011 | USA | 2002–2010 | 890 | 65 | 7 |
Narita et al. | 2011 | France | 1996–2009 | 753 | 80 | 11 |
Stella et al. | 2012 | France | 1995–2009 | 1042 | 56 | 5 |
Bowers et al. | 2012 | UK | 2004–2010 | NR | 33 | NR |
Tanaka et al. | 2012 | Japan | 2003–2011 | 232 | 24 | 10 |
Turrini et al. | 2012 | France | 2000–2010 | NR | 48 | NR |
Muratore et al. | 2012 | Italy | 1997–2009 | 653 | 47 | 7 |
Cardona et al. | 2014 | USA | 2000–2009 | 1188 | 40 | 3 |
Giuliante et al. | 2014 | Italy | 2002–2011 | NR | 130 | NR |
Faitot et al. | 2015 | France | 2004–2010 | NR | 50 | NR |
Imai et al. | 2015 | France | 2000–2012 | 845 | 125 | 15 |
Concomitant Extrahepatic Disease
Previous studies reported the rate of concomitant extrahepatic disease to be ranged from 0 to 33% in patients who were planned for TSH (Table 13.2). At Paul Brousse Hospital, the presence of extrahepatic metastases is not considered a contraindication for hepatectomy if these are limited and resectable. When limited extrahepatic disease is located in the abdominal cavity (i.e. pedicular lymph node or peritoneal metastases), resection is performed at the time of first-stage hepatectomy. When extrahepatic disease is located outside the abdomen (such as lung metastasis), resection is usually performed 2–3 months after the second-stage hepatectomy, provided that the disease remains controlled by chemotherapy. In our recent study (2000–2012), concomitant extrahepatic disease was observed in 26% of the patients who were planned for TSH [12]. Among them, resection of concomitant extrahepatic disease was consequently achieved in 42%. Remaining concomitant extrahepatic disease was not resected mainly because of disease recurrence after second-stage hepatectomy or in cases of TSH failure. In our treatment strategy, the presence of extrahepatic disease was neither a predictive factor of TSH failure nor a prognostic factor of survival after TSH (unpublished data). What is crucial however, is to envisage resection of concomitant extrahepatic disease when the disease is controlled by chemotherapy.
Table 13.2
Perioperative features at first-stage hepatectomy
Concomitant extrahepatic disease (%) | Preoperative chemotherapy (%) | Simultaneous resection of primary tumor (%) | Major resection (%) | Concomitant use of local ablation therapy (%) | Intraoperative PVE/PVL (%) | Morbidity (%) | Mortality (%) | |
---|---|---|---|---|---|---|---|---|
Lygidakis et al. | NR | NR | 100 | 0 | 100 | 100 | 11 | 0 |
Garcea et al. | 0 | 100 | 0 | 28 | 0 | NR | NR | 0 |
Pamecha et al. | 0 | 100 | 0 | 14 | 0 | 0 | 0 | 0 |
Homayounfar et al. | 4 | 75 | 0 | 0 | 29.2 | 100 | 13 | 0 |
Tsai et al. | 7 | 71 | 49 | 25 | 23 | 73 | 26 | 4 |
Karoui et al. | 12 | 61 | 100 | 0 | 15 | 52 | 21 | 0 |
Tsim et al. | 0 | 97 | 0 | NR | 0 | 0 | 11 | 0 |
Brouquet et al. | 0 | 100 | 29 | 3 | 3 | 0 | 25 | 0 |
Narita et al. | 14 | 84 | 31 | 0 | 32 | 4 | 14 | 0 |
Stella et al. | 6 | 96 | 49 | 4 | 76 | 61 | 37 | 0 |
Bowers et al. | 0 | 85 | 31 | 23 | 9 | 3 | 23 | 0 |
Tanaka et al. | 33 | 100 | NR | 5 | 0 | 86 | 29 | 0 |
Turrini et al. | 0 | 100 | 37 | 0 | 67 | 0 | 10 | 0 |
Muratore et al. | 26 | 79 | 0 | 4 | 0 | 23 | 19 | 0 |
Cardona et al. | 0 | 100 | 100 | 2 | 9 | 9 | 14 | 0 |
Giuliante et al. | 26 | 87 | 55 | 3 | 4 | 52 | 17 | 0 |
Faitot et al. | 10 | 90 | NR | NR | 38 | 88 | 18a | 2 |
Imai et al. | 26 | 98 | 30 | 2 | 10 | 76 | 14a | 1 |
Surgical Procedures of TSH
First-Stage Hepatectomy
At Paul Brousse Hospital, during the first-stage hepatectomy, either the most invaded hemiliver (usually the right) is resected, or, in most cases, the less-invaded liver lobe (FLR) is cleared of its metastases [10, 12, 13]. In the literature, limited hepatectomy (<3 segments) was mainly performed during first-stage hepatectomy (Fig. 13.2). Clearance is generally obtained by non-anatomical resection (Fig. 13.2a), and local ablation therapy such as cryotherapy and radiofrequency ablation (RFA), is only used in combination with hepatectomy for the treatment of unresectable tumors deeply located in the FLR with the purpose of sparing liver parenchyma of the FLR. Portal vein ligation (PVL)/PVE is routinely performed intraoperatively during the first-stage. Previous studies reported that stimulation of liver hypertrophy could also accelerate intrahepatic tumor progression after PVE [14–17]. From this aspect, what is essential during first-stage hepatectomy is that all tumors in the FLR should be removed to avoid tumor regrowth, leading to the failure to proceed to second-stage procedure.
Fig. 13.2
Procedure of two-stage hepatectomy. (a) During the first-stage hepatectomy, in most cases, the less-invaded liver lobe is cleared of its metastases, usually by non-anatomical resection. (b) Ligation of right portal vein. (c) Embolization by dehydrated ethanol. For the safety of second-stage hepatectomy, portal vein ligation and embolization is routinely performed during first-stage hepatectomy
Portal Vein Ligation/Embolization
At Paul Brousse Hospital, for the safety of second-stage hepatectomy, PVE using dehydrated ethanol in combination with ligation is routinely performed during first-stage hepatectomy (about 82%) (Fig. 13.2b, c) [12]. If PVL/PVE is not performed during first-stage, percutaneous PVE is added after first-stage (about 18%). The volume of FLR is evaluated by volumetric computed tomography (CT) analysis 4–6 weeks later. Whether PVL/PVE is performed during or after first-stage hepatectomy seems to depend on institutions (Tables 13.2 and 13.3).
Table 13.3
Perioperative features at second-stage hepatectomy
Interval duration (days) | Interval PVE (%) | Interval chemotherapy (%) | Major hepate ctomy (≥3 segments) (%) | Concomitant use of local ablation therapy (%) | Morbidity (%) | Mortality (%) | |
---|---|---|---|---|---|---|---|
Lygidakis et al. | 40 | 0 | 100 | 77 | 0 | 11 | 3 |
Garcea et al. | 150 | NR | 0 | 78 | 0 | 33 | 0 |
Pamecha et al. | 210 | 35.7 | 100 | 73 | 0 | 27 | 0 |
Homayounfar et al. | 42 | 0 | 0 | 73 | 11 | 58 | 5 |
Tsai et al. | 135 | 4 | 62 | 80 | 17 | 26 | 6 |
Karoui et al. | 111 | 15 | 76 | 92 | 4 | 32 | 4 |
Tsim et al. | NR | 95 | 13 | NR | 0 | 33 | 0 |
Brouquet et al. | 32 | 70 | 19 | 85 | 0 | 49 | 0 |
Narita et al.
Stay updated, free articles. Join our Telegram channelFull access? Get Clinical TreeGet Clinical Tree app for offline access |